By Helena Smolak
Sanofi backed its full-year guidance after higher first-quarter sales and profit that beat analysts' expectations.
The French pharmaceutical company said Thursday that business operating profit--one of its preferred metrics, which strips out exceptional items--rose 20% to 2.90 billion euros, equivalent to $3.28 billion, driven by a higher gross margin and slower operating expense growth.
Sales rose 11% to 9.895 billion euros on higher demand for its key drugs and vaccines and a favorable base of comparison.
Analysts expected business operating profit of 2.68 billion euros on sales of 9.64 billion euros, according to a poll of analysts by Visible Alpha.
Its business earnings per share were up 17% at 1.79 euros.
Sanofi stuck to its guidance for the year, expecting sales to grow by a mid-to-high single digit and business EPS at a low double-digit percentage, both at constant currencies.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 24, 2025 01:30 ET (05:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。